Drugs for medical purposes, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Drugs for medical purposes, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Drugs for medical purposes, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Drugs for medical purposes, namely, anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Drugs for medical purposes, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antibiotics; Drugs for medical purposes, namely, adjuvant treatment of acute and chronic hepatitis; Pharmaceutical preparations, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Pharmaceutical preparations, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Pharmaceutical preparations, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Pharmaceutical preparations, namely, anticancer for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Pharmaceutical preparations, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Pharmaceutical preparations, namely, adjuvant treatment of acute and chronic hepatitis; Antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia

First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details

Serial Number

No 79344895

Mark Type

No Service/Collective Mark

Attorney Docket Number

44D Filed

44D Current

44E filed

44E Current

66A Filed

Yes

66A Current

Yes

Current Basis

No Basis

Design Code(s)

01.15.06 -

Clouds, fog

05.13.04 -

Bamboo, sugar cane

06.01.04 -

Mountains, mountain landscapes

26.01.02 -

Plain single line circles

28.01.03 -

Japanese and Chinese characters Formerly Inscriptions in Chinese, Japanese, Korean, Vietnamese or other Asian characters

Legal History

Status Date	Action Taken
11^th Aug 2024	FINAL DECISION TRANSACTION PROCESSED BY IB
21^st Jul 2024	FINAL DISPOSITION PROCESSED
21^st Jul 2024	FINAL DISPOSITION NOTICE SENT TO IB
20^th Jun 2024	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19^th Mar 2024	NOTICE OF REGISTRATION CONFIRMATION EMAILED
19^th Mar 2024	REGISTERED-PRINCIPAL REGISTER
07^th Jan 2024	NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02^th Jan 2024	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02^th Jan 2024	PUBLISHED FOR OPPOSITION
02^th Jan 2024	NOTIFICATION PROCESSED BY IB

MOGANSHAN

Classification Information

Class [005]Pharmaceutical Products